OBJECTIVE: Large inoperable sacral chordomas show unsatisfactory local control rates even when treated with high dose proton therapy (PT). The aim of this study is assessing feasibility and reporting early results of patients treated with PT and concomitant hyperthermia (HT). METHODS: : Patients had histologically proven unresectable sacral chordomas and received 70 Gy (relative biological effectiveness) in 2.5 Gy fractions with concomitant weekly HT. Toxicity was assessed according to CTCAE_v4. A volumetric tumor response analysis was performed. RESULTS: : Five patients were treated with the combined approach. Median baseline tumor volume was 735 cc (range, 369-1142). All patients completed PT and received a median of 5 HT sessions (range, 2-6). Median follow-up was 18 months (range, 9-26). The volumetric analysis showed an objective response of all tumors (median shrinkage 46%; range, 9-72). All patients experienced acute Grade 2-3 local pain. One patient presented with a late Grade 3 iliac fracture. CONCLUSION: Combining PT and HT in large inoperable sacral chordomas is feasible and causes acceptable toxicity. Volumetric analysis shows promising early results, warranting confirmation in the framework of a prospective trial. ADVANCES IN KNOWLEDGE:: This is an encouraging first report of the feasibility and early results of concomitant HT and PT in treating inoperable sacral chordoma.
OBJECTIVE: Large inoperable sacral chordomas show unsatisfactory local control rates even when treated with high dose proton therapy (PT). The aim of this study is assessing feasibility and reporting early results of patients treated with PT and concomitant hyperthermia (HT). METHODS: : Patients had histologically proven unresectable sacral chordomas and received 70 Gy (relative biological effectiveness) in 2.5 Gy fractions with concomitant weekly HT. Toxicity was assessed according to CTCAE_v4. A volumetric tumor response analysis was performed. RESULTS: : Five patients were treated with the combined approach. Median baseline tumor volume was 735 cc (range, 369-1142). All patients completed PT and received a median of 5 HT sessions (range, 2-6). Median follow-up was 18 months (range, 9-26). The volumetric analysis showed an objective response of all tumors (median shrinkage 46%; range, 9-72). All patients experienced acute Grade 2-3 local pain. One patient presented with a late Grade 3 iliac fracture. CONCLUSION: Combining PT and HT in large inoperable sacral chordomas is feasible and causes acceptable toxicity. Volumetric analysis shows promising early results, warranting confirmation in the framework of a prospective trial. ADVANCES IN KNOWLEDGE:: This is an encouraging first report of the feasibility and early results of concomitant HT and PT in treating inoperable sacral chordoma.
Authors: Lily Park; Thomas F Delaney; Norbert J Liebsch; Francis J Hornicek; Saveli Goldberg; Henry Mankin; Andrew E Rosenberg; Daniel I Rosenthal; Herman D Suit Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-06 Impact factor: 7.038
Authors: Thomas F DeLaney; Norbert J Liebsch; Frank X Pedlow; Judith Adams; Elizabeth A Weyman; Beow Y Yeap; Nicolas Depauw; G Petur Nielsen; David C Harmon; Sam S Yoon; Yen-Lin Chen; Joseph H Schwab; Francis J Hornicek Journal: J Surg Oncol Date: 2014-04-19 Impact factor: 3.454
Authors: Peyman Kabolizadeh; Yen-Lin Chen; Norbert Liebsch; Francis J Hornicek; Joseph H Schwab; Edwin Choy; Daniel I Rosenthal; Andrzej Niemierko; Thomas F DeLaney Journal: Int J Radiat Oncol Biol Phys Date: 2016-10-13 Impact factor: 7.038
Authors: Matthias Uhl; Thomas Welzel; Alexandra Jensen; Malte Ellerbrock; Thomas Haberer; Oliver Jäkel; Klaus Herfarth; Jürgen Debus Journal: Strahlenther Onkol Date: 2015-03-04 Impact factor: 3.621
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: N R Datta; S Gómez Ordóñez; U S Gaipl; M M Paulides; H Crezee; J Gellermann; D Marder; E Puric; S Bodis Journal: Cancer Treat Rev Date: 2015-05-27 Impact factor: 12.111
Authors: Brenton Pennicooke; Ilya Laufer; Arjun Sahgal; Peter P Varga; Ziya L Gokaslan; Mark H Bilsky; Yoshiya J Yamada Journal: Spine (Phila Pa 1976) Date: 2016-10-15 Impact factor: 3.241